About the Master

Jeffrey Cummings is a world-renowned neurologist, winner of the Bengt Winblad Lifetime Achievement Award (2018) from the US Alzheimer’s Association, and Professor at the Cleveland Clinic Lou Ruvo Center for Brain Health.

About the e-Class

The advent of GV-971 ended a long-endured standstill by becoming the first new drug worldwide approved for treating AD in the past 17 years. The China-developed AD drug, the first in the world that targets the gut-brain axis, reduces peripheral and central inflammation by reconditioning the gut microbiota and inhibiting the abnormal increase of gut microbiota-derived metabolites.